ASH 2015: As CAR-T Players Vie For 1st Place, Will Efficacy Trump Safety?
This article was originally published in Scrip
Executive Summary
Data for chimeric antigen receptor T-cell (CAR-T) therapies from Novartis AG, Kite Pharma Inc. and Juno Therapeutics Inc. have shown similarly impressive efficacy and safety, so the companies are vying for position as the first to market with a CAR-T therapy for hematological malignancies.
You may also be interested in...
Three Deaths In Trial Mean Clinical Hold For Juno’s Lead CAR-T Therapy
Juno Therapeutics Inc. planned to win US FDA approval in 2017 for its chimeric antigen receptor T cell (CAR-T) cell therapy JCAR015, but the company has reached another significant milestone that may delay that goal: its Phase II ROCKET clinical trial in the treatment of adults with relapsed or refractory B cell acute lymphoblastic lymphoma (ALL) has been put on clinical hold due to three deaths.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Need a specific report? 1000+ reports available
Buy Reports